SAGE Therapeutics, Inc. (US) (SAGE) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
SAGE Therapeutics, Inc. is currently embroiled in a federal securities class action lawsuit and an SEC investigation, which pose significant business risks. These legal challenges could lead to substantial financial liabilities and distract management from strategic priorities. The outcome of these proceedings is uncertain, and potential adverse rulings could negatively affect the company’s financial health and reputation. The management’s focus on these issues might hinder the execution of essential business strategies crucial for growth.
Overall, Wall Street has a Hold consensus rating on SAGE stock based on 2 Buys, 1 Sell and 14 Holds.
To learn more about SAGE Therapeutics, Inc. (US)’s risk factors, click here.
